Orexin-A levels in relation to the risk of metabolic syndrome in patient with schizophrenia taking antipsychotics

University of Taipei > 市政管理學院 > 衛生福利學系 > 期刊論文 > Item 987654321/17176

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://utaipeir.lib.utaipei.edu.tw/dspace/handle/987654321/17176

题名:	Orexin-A levels in relation to the risk of metabolic syndrome in patient with schizophrenia taking antipsychotics
作者:	Chen, P-Y;Chen, C-H;Chang, C-K;張慶國;Kao, C-F;Lu, M-L;Lin, S-K;Huang, M-C;Hwang, L-L;Mondelli, V
日期:	2018-09
上传时间:	2019-12-11 10:17:33 (UTC+8)
摘要:	BACKGROUND: The role of orexin-A in regulating metabolic homeostasis has been recognized, but its association with antipsychotic-induced metabolic abnormalities remains unclear. We investigated the association between orexin-A levels and metabolic syndrome in patients with schizophrenia treated with clozapine or less obesogenic antipsychotics compared with nonpsychiatric controls. METHODS: Plasma orexin-A levels and metabolic parameters were determined in 159 patients with schizophrenia: 109 taking clozapine; 50 taking aripiprazole, amisulpride, ziprasidone, or haloperidol; and 60 nonpsychiatric controls. RESULTS: Orexin-A levels were significantly higher in the group taking less obesogenic antipsychotics, followed by the clozapine group and the controls (F=104.6, P<.01). Higher orexin-A levels were correlated with better metabolic profiles in the patient groups but not in the controls. Regression analyses revealed that the patients with higher orexin-A levels had significantly lower risk of metabolic syndrome (adjusted odds ratio [OR]=0.04, 95% CI: 0.01-0.38 for the 2nd tertile; OR=0.04, 95% CI: 0.01-0.36 for the 3rd tertile, compared with the first tertile), after adjustment for age, sex, smoking history, types of antipsychotics (clozapine vs less obesogenic antipsychotics), duration of antipsychotic treatment, and disease severity. CONCLUSIONS: Our results revealed that the orexin-A level was upregulated in patients with schizophrenia treated with antipsychotics, especially for the group taking less obesogenic antipsychotics. Furthermore, higher orexin-A levels were independently associated with better metabolic profiles. These observations suggest that an upregulation of orexin-A has a protective effect against the development of metabolic abnormalities in patients with schizophrenia receiving antipsychotic treatment.
關聯:	International Journal of Neuropsychopharmacology
显示于类别:	[衛生福利學系] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在uTaipei中所有的数据项都受到原著作权保护.

数据加载中.....